ClinicalTrials.gg
RecruitingNCT07434726CPReboaUpdated Aug 21, 2026

In-hospital Cardiopulmonary Resuscitation With Balloon Occlusion of the Descending Aorta

An interventional study of resuscitative endovascular occlusion of the aorta (REBOA) and Advanced Cardiac Life Support (ACLS) in Cardiac Arrest, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Heart Arrest with a site in Switzerland — 5 open to participants now, 6 under way, none of them phase 3. Heart Arrest · Switzerland.

Planned enrollment
8th of 17
98 · median 54
Started
2026
the only one that year
No phase
16 of 29
2 open now
Registered
28th of 29
by date
Lead sponsor
5 of 29
Insel Gruppe AG, University Hospital Bern

Among the 29 studies in Heart Arrest with a site in Switzerland, this one is the 8th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2026, is one of 16 with no phase, and was the 28th registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

5 of the 29 studies in Heart Arrest with a site in Switzerland are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Heart Arrest with a site in Switzerland, or all of them as a file.
02

Study summary

This study will test if a sustained Return of Spontaneous Circulation (ROSC) in patients with cardiac arrest is more frequent when patients receive advanced cardiac life support (ACLS) alone or when they receive ACLS plus a balloon occlusion of the thoracic aorta.

Read the detailed description

Patients with in-hospital cardiac arrest (IHCA) outside the operating room, the coronary angiography suite and the intensive care unit (ICU) will be attended to by the hospitals resuscitation team and provided with advanced cardiac life support (ACLS) as per usual practice.

A research team will be deployed simultaneously and, when patients meet inclusion criteria, will randomize patients to ACLS alone or to ACLS plus balloon occlusion of the descending thoracic aorta by means of a resuscitative endovascular occlusion of the aorta (REBOA) catheter.

03

Conditions studied

  • Cardiac Arrest

Browse trials for

Keywords

  • Cardiac Arrest
  • resuscitative endovascular occlusion of the aorta REBOA
  • cardio pulmonary resuscitation CPR
  • advanced cardiac life support ACLS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients suffering from in hospital cardiac arrest (IHCA), including patients with out of hospital cardiac arrest (OHCA) and return of spontaneous circulation (ROSC), transported to the emergency department, where they suffer a second arrest (IHCA)
  • successful placement of a femoral artery introducer sheath
  • any electrical cardiac activity seen in the initial rhythm analysis
  • ongoing effort of resuscitation as determined by study-independent resuscitation lead

Exclusion criteria

Exclusion criteria:

  • IHCA in the operating room, on intensive care unit or in the cardiac catheter laboratory
  • hospital visitors suffering from cardiac arrest
  • asystole seen in the initial rhythm analysis
  • (presumed) age under 18 years
  • known "do not resuscitate"-order
  • known or obvious pregnancy
  • traumatic cardiac arrest
  • known aortic pathologies that render cannulation impossible
  • known allergies to radiographic contrast agents
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
98 participants (estimated)

Study arms

  • Active comparator
    Advanced Cardiac Life Support (ACLS) alone

    Advanced Cardiac Life Support (ACLS) as per the hospitals standard protocol, including advanced interventions such as extended cardio-pulmonary resuscitation (eCPR).

    Other: Advanced Cardiac Life Support (ACLS)

  • Experimental
    Advanced Cardiac Life Support (ACLS) plus REBOA

    Advanced Cardiac Life Support (ACLS) as per the hospitals standard protocol, including advanced interventions such as eCPR plus resuscitative balloon occlusion of the descending thoracic aorta (REBOA).

    Device: resuscitative endovascular occlusion of the aorta (REBOA) · Other: Advanced Cardiac Life Support (ACLS)

Interventions

  • Deviceresuscitative endovascular occlusion of the aorta (REBOA)

    Insertion of a balloon catheter through the common femoral artery, retrograde advancement of the catheter into the descending thoracic aorta, ballon occlusion of the aorta

  • OtherAdvanced Cardiac Life Support (ACLS)

    Advanced Cardiac Life Support (ACLS) as per American Heart Association (AHA) or European Resuscitation Council (ERC) standards

06

What researchers measure

Primary outcomes

  1. Sustained ROSC

    Any return of spontaneous circulation lasting longer then 20 minutes

    Time frame: Up to 1 hour after study inclusion

Secondary outcomes

  1. Survival to hospital discharge

    dead or alive

    Time frame: at hospital discharge, up to 90 days after study inclusion

  2. Survival to six month

    dead or alive

    Time frame: 6 month after study inclusion

  3. neurologic outcome at the time of 30 days

    measured by means of modified ranking scale

    Time frame: Day 30 after study inclusion

  4. neurologic outcome at the time of six month

    measured by means of modified ranking scale

    Time frame: 6 month after study inclusion

  5. ICU-free days before hospital discharge

    Time frame: at hospital discharge, up to 90 days after study inclusion

  6. ICU-free days at 30 days

    Time frame: 30 days after study inclusion

Other outcomes

  1. non-invasive cerebral oxygenation during resuscitation

    Exploratory, measured in %

    Time frame: Continuously assessed during ongoing resuscitation, up to 1 hour after study inclusion

  2. cause of death

    exploratory, written description

    Time frame: at six month

  3. Troponin T trajectory

    exploratory

    Time frame: at inclusion, 30 minutes after inclusion and once up to day 3

  4. Neuron-Specific Enolase (NSE) trajectory

    exploratory

    Time frame: at inclusion, 30 minutes after inclusion and once up to day 3

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Gaube LM, Sparks ED, Iten M, Knapp J, Furholz M, Schefold JC, Hunziker Munsch L, Hanggi M, Krummrey G, Muller M, Hautz WE. In-hospital cardiopulmonary resuscitation with balloon occlusion of the descending aorta: protocol of the randomised controlled CPReboa study. BMJ Open. 2026 Aug 11;16(8):e119691. doi: 10.1136/bmjopen-2026-119691. PubMed 42580829 ↗

Individual participant data

Plan to share: Yes — All IBD (including data dictionaries) will be shared upon reasonable request with researcher eligible health data under Swiss legislation. Eligibility will be determined by Cantonal Ethics Committee of Bern. This determination will require submission of a research plan to the ethics committee. Data will be provided as electronic files in STATA file format as exported from the RedCap study database. The trials study protocol is available on the trial website at http://cpreboa.org. The statistical analysis protocol will become available on the trial website an in the Zenodo registry before inclusion of the last patient into the trial.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: After publication of the trial results. Data will remain available for five years.

Access criteria: Upon reasonable request to researcher eligible to work with coded individual biological, non-genetic health data under Swiss legislation - see above.

Data sharing details ↗ · cpreboa.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2030, 56 months after the start.

Of 205 non-industry interventional studies with no phase under Heart Arrest, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 47. This study's planned 56 months is above that.

Counting every sponsor, half of 219 studies reached it within 28 months; a quarter within 10 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 27, 2026
StartActual
Apr 14, 2026
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07434726
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Apr 14, 2026
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Aug 21, 2026

Study contacts

Tanja Birrenbach, MD, MME
Contact
tanja.birrenbach@insel.ch
+41 31 632 57 01
Cornelia Lammbrigger, RN
Contact
ukn.studynurse@insel.ch
+41 31 632 57 01
Tanja Birrenbach, MD, MME
principal investigator · Inselspital University Hospital Bern

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion